191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors

A. Jimeno, N.R. Miselis, J.C. Park, J. Jennings, N. Dhani, U. Holtick, W.T. Iams, K. Rodabaugh, N. Nair, M. Kornacker,S.M. Loughhead, H. Bernstein, R. Zwirtes, R.R. Ji, M. Warren,A. Sharei

Immuno-Oncology and Technology（2022）

引用 0|浏览1